To describe contemporary worldwide age-standardized incidence and mortality rates for bladder, kidney, prostate and testis cancer and their association with development.
Introduction
Genitourinary cancers account for 26% of the global cancer incidence and 13% of global cancer mortality. In developing countries, these malignancies are a more significant public health problem; 36% of all incident genitourinary cancers and 52% of all genitourinary cancer deaths occur in less developed regions [1] . Despite the rising burden of cancer in developing countries, according to the Global Task Force on Expanded Access to Cancer Care and Control, only 5% of global resources for cancer are spent in the developing world [2] . The relationship between economic development and global incidence and mortality rates of cancer is not well understood, but it is hypothesized that increased development is associated with improved access to healthcare resulting in early diagnosis and availability of treatment as well as differences in modifiable risk factors and exposures [3, 4] . We explored these relationships for genitourinary cancers and hypothesized that populations in developing countries would have a higher mortality rate relative to the incident rate of genitourinary malignancies when compared with rates in developed nations.
Materials and Methods

Data Sources
The GLOBOCAN 2012 database, maintained by the WHO International Agency for Research on Cancer, provides incidence and mortality estimates from regional and national cancer registries for 27 cancers in 184 countries and territories worldwide [5] . GLOBOCAN incidence data are derived from national and multinational population-based cancer registries, primarily from Cancer Incidence in Five Continents [6] . Mortality data are collected by the WHO and generated from death registration systems in each country. Detailed information on the methods used to generate incidence and mortality estimates for each country is available on the GLOBOCAN website and has been described previously [1, 5] . If the availability of annual data was minimal, GLOBOCAN applied simple time-linear models or age-period cohort models depending on the period in which data were available to predict incidence and mortality in 2012 [7] .
To estimate economic status by country, we used the United Nations Human Development Index (HDI; www.hdr.undp. org). The HDI is a measure of national well-being based on three general indicators: life expectancy, education and income. In 2014, a system of fixed cut-off values for the four categories of human development achievements was introduced into the HDI which were used to define very high, high, medium and low human development.
We derived gender-specific age-standardized incidence rates (ASIRs) and age-standardized mortality rates (ASMRs) from the GLOBOCAN database. ASIR and ASMR were calculated using a weighted mean of the age-specific rates taken from the population distribution of the world standard population using 10 age groups [8] . Estimates for all countries as well as predefined WHO regions were obtained directly from GLOBOCAN (http://globocan.iarc.fr/), which used populationweighted averages of incidence and mortality data from member countries.
The ASMR-to-ASIR ratio was derived as a surrogate measure of health system effectiveness. This mortality-to-incidence ratio (MIR) was proposed as an indirect measure of true biological differences in disease phenotype or health system-related attributes, including screening, diagnostic techniques, treatment and follow-up [9] . This ratio, which is synonymous with the fatality or lethality rate, has been used to estimate the 5-year survival of patients with cancer, with the understanding that a simple relationship does not exist between mortality and incidence for all cancers [10] . The MIR provides a standard, population-based approximation of survival by stabilizing incidence and mortality differences across geographic cancer sites. It can serve as a surrogate to assess the proficiency of diagnosing and effectively treating urological cancer in each country.
We assessed the relationship of HDI to MIR using univariate linear regression. Data were available for 175 countries for bladder cancer, 169 countries for kidney cancer, 174 countries for prostate cancer and 153 countries for testis cancer. We excluded outlier nations from analysis that had MIR values of 0, 1 or >1.
Results
Bladder Cancer
Worldwide, the ASIR for bladder cancer was 5.3 cases per 100 000 individuals; however, the incidence rate varied 7.5-fold worldwide, with the highest ASIRs in Southern Europe (12/100 000 individuals), Northern America (11.6) and Western Europe (11.4) , and the lowest in Western Africa (1.6), Asia (2.2-2.5) and Central America (2.5 [ Fig. 1A] ). The ASIR was 2.9 times higher in more vs less developed countries.
The global ASMR for bladder cancer was 1.9 deaths per 100 000 individuals. Mortality patterns did not follow those of incidence, with the highest ASMR noted in Western Asia (4.6 per 100 000) and Northern Africa (4.4), and the lowest ASMR in Central America (0.9) and Western Africa (1.1 [ Fig. 1A] ). The ASMR was 1.6 times higher in more vs less developed countries.
The MIR for bladder cancer was higher in less developed countries compared with developed nations (0.48 vs 0. 
Kidney Cancer
Worldwide, the ASIR for kidney cancer was 4.4 cases per 100 000 individuals. The incidence rate varied 17-fold worldwide, with the highest ASIRs in North America (11.7/100 000 individuals), Western, Central and Eastern Europe (8.7-9.8) and Australia (9.3), and the lowest in Western Africa (0.7), South-Central Asia (1) and Southern Africa (1.1 [ Fig. 1B]) . The ASIR for kidney cancer was 3.5 times higher in more vs less developed countries.
The global ASMR for kidney cancer was 1.8 deaths per 100 000 individuals. Mortality followed incidence patterns, with the highest ASMR in Western, Central, Eastern Europe (2.5-3.6) and North America (2.6), and the lowest ASMR in Western Africa (0.6), South Central Asia (0.7) and Southern Africa (1 [Fig. 1B] ). The ASMR was 2.2 times higher in more vs less developed countries.
The MIR for kidney cancer was higher in less developed countries compared with developed nations (0.5 vs 0.3 [ Fig. 2] ). The worldwide MIR was highest in Africa (0.75-0.91), and lowest in North America and Australia (0.22-0.24 [ Fig. 3] ). Linear regression analysis showed a strong relationship between HDI and MIR (Fig. 4B) .
Prostate Cancer
Worldwide, the ASIR for prostate cancer was 30.6 cases per 100 000 individuals; however, the incidence rate varied widely worldwide, with the highest ASIRs in North America, Europe and Australia (85-111/100 000) and the lowest in Asia and The global ASMR for prostate cancer was 7.8 deaths per 100 000 individuals. Mortality patterns did not match those of incidence patterns, with the highest ASMR in Southern, Western and Eastern Africa (18.7-24.4 ) and the lowest ASMR in South-Central and Eastern Asia (2.9-3.1 [ Fig. 1C] ). The ASMR was 1.5 times higher in more vs less developed countries.
The MIR for prostate cancer was higher in less developed countries compared with developed nations (0.66 vs 0.21 [ Fig. 2]) . Worldwide, the MIR was highest in Western, Eastern and Northern Africa (0.66-0.84), and lowest in North America, Western Europe and Australia/New Zealand (0.10-0.12) (Fig. 3) . Linear regression analysis showed a very strong inverse relationship between HDI and MIR (Fig. 4C ).
Testis Cancer
Worldwide, the ASIR for testis cancer was 1.5 cases per 100 000 individuals; however, the incidence rate varied 29-fold worldwide, with the highest ASIRs in Europe (7.2-8.7/100 000) and Australia/New Zealand (6.8) and the lowest in the African regions (0.3-0.6) and the Asian regions (0.4-1.7 [ Fig. 1D] ). The ASIR for testis cancer was 7.4 times higher in more vs less developed countries.
The global ASMR for testis cancer was 0.3 deaths per 100 000 individuals. Mortality patterns did not vary across regions, with the highest ASMRs in Central America (0.6) and Western Asia (0.7) and the lowest ASMR in Eastern Asia (0.1 Fig. 3] ). Linear regression analysis showed the strongest inverse relationship between HDI and MIR of the genitourinary cancers studied (Fig. 4D ).
Discussion
Cancer burden is a significant problem in developing countries, with 57% of the 14.1 million new cancer cases and 65% of the 8.2 million cancer deaths occurring in less developed regions. Despite the rising burden of cancer in developing countries, only 5% of global resources for cancer are spent in the developing world [2] . As an example, cancer care investment is disproportionately low in Africa, where 15% of the world population with its share of 6% of the world's annual new cases of cancer, receives only 0.3% of global cancer costs [11] . Inadequate cancer care spending in Africa is attributable to a complex variety of reasons, including lack of awareness of the disease burden, weak advocacy on behalf of local governments, heavy reliance on foreign aid, and training deficits, all of which result in inadequate infrastructure and personnel dedicated to cancer care [12] . Given these disparities in investment and resource availability for healthcare infrastructure in the developing world, some have suggested that the most feasible methods to reduce global health disparities include targeting aetiological factors and high-risk behaviours as well as developing strategies for cancer prevention [13] . In addition to targeting prevention strategies, valuable targets for healthcare investment include access to radiotherapy and chemotherapy services. Evaluation of the principal therapeutic means used to cure patients with cancer found that surgery was the primary method in 49% of patients, radiation in 40% of patients, and chemotherapy in 11% of patients [14] ; however, in developing countries where access to surgical specialization is inadequate, up to 60-70% of patients require radiotherapy as primary treatment for their cancer [15] . Unfortunately, the gap between radiotherapy demand and supply is growing in the developing world, with a deficit of >7 000 machines worldwide [16] . In Africa, only 277 external beam radiotherapy machines are in service over the entire continent, with 60% of those machines located in two countries (South Africa and Egypt), while 29 African countries report no access to radiotherapy machines [12] . Similarly, an analysis of the availability of cancer therapy drugs in Tanzania showed that >70% of patients do not receive adequate chemotherapy treatment, and that the treatment that is available costs between 2.7 and 6.1 times more than the international reference price [12, 17] .
Solutions have been identified that may be able to influence outcome disparity in genitourinary cancer among less developed countries. Complex strategies for scaling up cancer care have been proposed and include: educating the public; improving transportation and access to care; addressing the shortage of healthcare specialists in oncological fields and the and improving diagnosis and treatment resources [18] . As part of a cancer control plan, structuring and coordinating of cancer services should be addressed. This requires an accurate estimate of the burden of cancer in the country of interest, which remains a challenge in developing countries such as Africa, where few national population-based cancer registries exist [19] . Another important issue is the expansion of specialized healthcare providers; where localized training is not possible, public-private partnerships between medical institutions in the developed and developing world may provide solutions to the lack of trained clinicians. Success has been achieved with this model in Guatemala, Brazil and China, where public-private partnerships were formed to establish sustainable national paediatric oncology units. This success was achieved, first and foremost, by assessing the current status of paediatric oncology through the context of political, economic and cultural characteristics. In-depth evaluation of country-specific cancer healthcare economics, including government expenditure and charitable organization involvement, is necessary to form the basis of a realistic action plan [20] . A strong local advocate, dedicated local grassroots organizations, and a project mentor are deemed crucial to the success of these sustainable oncology units [20] . When a healthcare programme is established in the developing world by means of a public-private partnership, constant critical evaluation of the programme is essential to foster growth and sustainability [21] . Once success is achieved, the systems-based approach should be published to encourage replication, as Efsthathiou et al. [21] have done by detailing their success in establishing and delivering quality radiation therapy in Botswana.
To reduce global cancer disparities, it is important to understand these disparities in investment for healthcare infrastructure in the developing world and how that affects cancer outcomes. This allows us to develop a model for identifying valuable targets for healthcare investment for 'development-responsive' cancers. We identified varying degrees of association between the level of development of a country and the incidence and mortality of genitourinary malignancies worldwide. The MIRs of all genitourinary cancers are probably commonly influenced by access to preventive and acute medical services, but there are likely to be disease-specific factors that influence the strength of the MIRs observed for the various cancers studied.
Bladder Cancer
Tobacco contains aromatic amines known to cause bladder cancer and is the most important risk factor for bladder cancer in most parts of the world, with an attributable risk of up to 50% [22] [23] [24] . Smokers have a two-to fivefold increased risk of bladder cancer relative to never-smokers [25] , with a doseresponse relationship reported with increased smoking intensity, pack-years, and duration. Compared with nonsmokers, the risk of bladder cancer is twofold higher for those who smoke 10 cigarettes a day compared with threefold higher for those who smoke 30 cigarettes a day. Similarly, those with a 40-pack-year smoking history have a threefold increased risk compared with the twofold increased risk observed in those with a 20-pack-year history, compared with non-smokers. This relationship plateaus after smoking 15 cigarettes a day and 50 pack-years [26] . Black (air-cured) tobacco, which is associated with a two-to fivefold higher exposure to carcinogenic aromatic amines such as 4-aminobiphenyl [27] , may be associated with a commensurate two-to threefold increased risk of bladder cancer compared with blond (flue-cured) tobacco [28, 29] ; however, after controlling for depth of inhalation, no difference between black and blond tobacco and the risk of developing bladder cancer has been identified [30] . For bladder cancer, primary prevention of tobacco use is the most effective strategy for reducing disease-specific mortality.
According to the Centers for Disease Control, smoking cessation is becoming more common in more highly educated and health-focused populations and may explain how the bladder cancer burden is becoming re-distributed as smoking trends change internationally. The prevalence of adult tobacco smokers in the USA has decreased dramatically in the last 50 years, from 43% in 1965 to recent estimates of 19% [31] . Smoking remains more common among those who live below the poverty level, are mentally and physically disabled, and are less educated. This is thought to be in part attributable to disparities in education, with differences in understanding the health consequences of smoking and increased vulnerability to tobacco marketing. According to the WHO 2016 health statistics, although smoking is declining worldwide, the prevalence of tobacco smoking appears to be increasing in the Eastern Mediterranean and in Africa. At present, smoking prevalence is highest among men in the Western Pacific (48.5%) and Europe (39%) and is lowest in the Americas (22.8%) and Africa (24.2%). Among women, smoking prevalence is highest in Europe (19.3%) and the Americas (13.3%) and is lowest in Africa (2.4%), and South-East Asia (2.6%) [32] .
Roughly 7-20% of all bladder cancers are related to occupational exposure to carcinogens, including aromatic amines and polycyclic aromatic hydrocarbons [33] . These industries include petroleum, metal, paint, print and dye processing plants. Several studies have proposed that a reduction in occupational exposure may also contribute to a decline in incidence rates of bladder cancer in developing countries; however, this has been difficult to prove, given the lack of large epidemiological studies assessing occupational exposures [34] .
Finally, while the relatively high incidence of bladder cancer in North Africa was previously attributed to Schistaosoma haematobium, with the successful control of schistosomiasis, Egypt has experienced a decrease in squamous cell carcinoma of the bladder from 73% to 25%. There has been a commensurate increase in the proportion of TCC from 20% to 66%, occurring later in life and thought to be attributable primarily to smoking [35] .
Kidney Cancer
Increasing incidence of kidney cancer in developed countries with a lower associated mortality rate is in large part attributable to increased frequency and quality of crosssectional imaging [36] . This is in part evidenced by the fact that smaller masses are being identified at presentation with a combined increase in stage I disease compared with stages II-IV, and a subsequent stabilization or decrease of mortality trends being observed in developed countries [37] [38] [39] .
In both developing and developed countries, an increasing prevalence of risk factors, such as hypertension and diabetes, may also be playing a role in the increased incidence of kidney cancer. Three-quarters of the 415 million people living with diabetes worldwide live in developing countries [40] . While the prevalence of hypertension is only 23% in developing nations compared with 37% in the developed world, the absolute number of patients affected by hypertension is considerably higher in developing nations and continues to rise as increased globalization leads to increased rates of hypertension and diabetes and improvement in infectious diseases lead to longer life expectancy [41] . Observational and perspective studies have shown that hypertension is associated with an increased risk of kidney cancer incidence and mortality [42, 43] . Similarly, prospective studies have shown a strong linear relationship between obesity and the subsequent diagnosis of RCC [37, [44] [45] [46] .
As with bladder cancer, tobacco smoking is the best recognized risk factor for kidney cancer [39] , and we refer to the discussion on smoking in the bladder cancer section as an additional factor associated with the redistribution of the 
Prostate Cancer
Prostate cancer was found to have a very strong association between development and the incidence and mortality of prostate cancer globally; consistent with previously published single-country reports [3, 47, 48] . The incidence of prostate cancer has been linked to numerous factors, including life expectancy, lifestyle, diet and public access to prostate cancer screening. The incidence of prostate cancer is directly correlated with age, with 75% of new prostate cancer cases occurring in people aged >85 years [3, 49] . Developed countries have a higher life expectancy than developing countries, in part because of lower rates of death from infectious disease. This increase in life expectancy, along with improved prostate cancer screening, helps to explain in part why the incidence of prostate cancer is greater in countries with a high HDI [50] . Berglund et al. [48] and Shafique and Morrison [47] found a positive correlation between prostate cancer mortality and lower socio-economic status, which they termed the 'deprivation gap'. This seemed to be driven by access to diagnostic services and screening tests resulting in increased diagnosis at earlier stages of disease [51] .
Host-related factors, such as nutritional status, body mass index, tobacco and alcohol consumption, as well as other medical comorbidities, may contribute significantly to prostate cancer mortality reduction in developed countries. Risk factors such as heavy smoking or alcohol consumption are more prevalent in individuals of low socio-economic status [4] . A recent meta-analysis of 24 prospective studies by Islami et al. [52] showed a modest but statistically significant association between cigarette smoking and increased risk of death from prostate cancer. Similarly, a 30-year prospective cohort study of Finnish twins by Dickerman et al. [53] found that, compared with light drinkers, heavy drinkers and binge drinkers were at a higher risk of developing prostate cancer. Louwman et al. [54] found that patients with cancer who had low socio-economic status had a higher prevalence of comorbid conditions, and that 22% of social variations in 1-year survival among patients with prostate cancer could be attributed to differences in comorbidity burden.
Disparities in treatment availability for prostate cancer have also been observed. In the Middle East and North Africa, a survey of urologists found that awareness of the existence of National Comprehensive Cancer Network guidelines on prostate cancer varied between 5% and 86% [55] . Whereas, in the USA~26% of all patients diagnosed with prostate cancer undergo primary radiation therapy [56] , access to radiation equipment and the cost of neoadjuvant hormonal therapy limit availability of this treatment in developing countries. Although the data regarding the proportion of patients with prostate cancer worldwide undergoing treatment with radiation therapy is lacking, we know that in the developing world, more patients with prostate cancer present at an advanced stage, arguing that there may be greater need for radiation therapy in the developing world [57] . As previously discussed, access to radiation therapy is linked to a country's wealth; up to 36 countries worldwide have no radiation capabilities and, in the developing world, only 40-50% of the radiation service needs are being met [21] . As such, targeted interventions increasing access to radiation therapy may improve prostate cancer survival and improve the observed MIR in countries in the developing world.
Testicular Cancer
Testicular cancer incidence rates vary 29-fold worldwide, with the highest overall incidence found in Europe, Australia, New Zealand and the USA. Although mortality patterns did not vary much across regions, given the large variation in incidence, the MIR was found to be much higher in less developed countries compared with developed nations (0.06 vs 0.43). This finding suggests that, in developing regions, more patients die from their disease than in developed regions. With the advent of effective treatments such as platinum-based chemotherapy, testicular cancer has been one of the most curable neoplasms [39, 58] . The discrepancy in MIR between developed and developing countries is probably attributable to suboptimal access to healthcare and curative chemotherapy in developing regions, resulting in a diagnostic delay as well as inadequate availability of effective multimodal treatments [39, 59, 60] . In the USA, a review of practice patterns indicated that, for stage 1 seminoma, 75-83% of patients elected to pursue adjuvant radiotherapy and~8% elected to receive adjuvant chemotherapy [61] . In comparison, a review of patients presenting with testicular cancer in Nigeria showed that the most common histological subtype of testicular cancer was seminoma, but only 8% of patients presented with stage 1 disease while 33% of patients presented with stage 4 disease. While 46% received radical orchiectomy and cisplatin-based chemotherapy, only 25% of patients received radiotherapy after orchiectomy, and no patients underwent retroperitoneal lymph node dissection. Those patients who did receive radiation therapy were referred to centres in other cities at least 600 km away. Furthermore, 20% of patients had died within 19 months of presentation and half of the patient population was lost to follow-up within 24 months [62] . The infrastructure to care for patients with testicular cancer and identify late relapse and salvage patients not cured by primary treatment remains lacking in the developing world, and improvements in these processes may improve testicular cancer outcomes in these countries.
There are inherent limitations to the datasets used for the present analysis, which should be interpreted with caution.
GLOBOCAN incidence data quality and consistency are difficult to assess in some countries. Where incidence data are not available from a population-based cancer registry for the entire nation, GLOBOCAN often extrapolates data for developing nations based on data from smaller subnational areas or major cities in those developing nations. As such, ASMRs and ASIRs may not accurately reflect the true incidence and mortality for developing nations across their entirety. Additionally, while HDI is the 'gold standard' for international comparisons of development, there is debate regarding using this metric as a composite measure of development. Furthermore, discrepancies between the reliability of incidence and mortality reporting limit MIR interpretation. This is mainly because mortality data are generally more accurate than incidence data in developing countries. Finally, as this is a cross-sectional univariate analysis, the increase in MIR cannot be directly attributed to development status, but, importantly, it serves to inform health policy-makers on areas of future research and healthcare investment.
In conclusion, we identified a significant and positive inverse correlation between development and mortality and incidence in prostate, bladder, testis and kidney cancer. More developed countries are more likely to have higher ASIRs and ASMRs, but lower MIRs. This association suggests that development plays an important role in the relationship between genitourinary cancer diagnosis and mortality. Targeting of developmentsensitive malignancies, such as genitourinary cancers, will arguably result in the greatest improvements in disparate cancer outcomes compared with those malignancies where no correlation between development and mortality exist. Further research is needed to understand whether difference in comorbidities, exposures, time to diagnosis, or treatment explain observed inequalities in genitourinary cancer outcomes.
